Various biologics are used for the treatment of psoriasis in clinical practice; these include secukinumab (a fully humanized anti-IL-17A IgG1κ monoclonal antibody), ixekizumab (a humanized anti-IL-17A IgG4 monoclonal antibody), ustekinumab (a humanized anti-IL-12/23 p40 subunit IgG1κ monoclonal antibody), guselkumab (a fully humanized anti-IL-23 p19 subunit IgG1 monoclonal antibody), and risankizumab (a fully humanized anti-IL-23 p19 subunit IgG1λ monoclonal antibody). The gene discussed is IL17A; the disease is psoriasis.